JP2013079218A5 - - Google Patents

Download PDF

Info

Publication number
JP2013079218A5
JP2013079218A5 JP2011220787A JP2011220787A JP2013079218A5 JP 2013079218 A5 JP2013079218 A5 JP 2013079218A5 JP 2011220787 A JP2011220787 A JP 2011220787A JP 2011220787 A JP2011220787 A JP 2011220787A JP 2013079218 A5 JP2013079218 A5 JP 2013079218A5
Authority
JP
Japan
Prior art keywords
formed product
product according
lactoferrin
set formed
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011220787A
Other languages
Japanese (ja)
Other versions
JP5899773B2 (en
JP2013079218A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2011220787A priority Critical patent/JP5899773B2/en
Priority claimed from JP2011220787A external-priority patent/JP5899773B2/en
Publication of JP2013079218A publication Critical patent/JP2013079218A/en
Publication of JP2013079218A5 publication Critical patent/JP2013079218A5/ja
Application granted granted Critical
Publication of JP5899773B2 publication Critical patent/JP5899773B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (4)

ラクトフェリンを有効成分として含有することを特徴とする更年期障害改善及びＱＯＬ改善用組成物。 Menopause improvement and QOL improved for assembly forming product characterized by containing lactoferrin as an active ingredient. 経口製剤である、請求項１記載の組成物。 We are an oral formulation, according to claim 1 set formed product according. 腸溶性製剤である、請求項１又は２記載の組成物。 Is enteric preparation, according to claim 1 or 2 pairs formed product according. ラクトフェリンの１日あたりの投与量が１０mg乃至１５，０００mgである、請求項１〜３のいずれか１項記載の組成物。
The daily dose of lactoferrin is 10mg to 15,000, any one set formed product according to claims 1-3.
JP2011220787A 2011-10-05 2011-10-05 Pharmaceutical composition for improving menopause and food and drink Active JP5899773B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011220787A JP5899773B2 (en) 2011-10-05 2011-10-05 Pharmaceutical composition for improving menopause and food and drink

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011220787A JP5899773B2 (en) 2011-10-05 2011-10-05 Pharmaceutical composition for improving menopause and food and drink

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016017614A Division JP6082941B2 (en) 2016-02-02 2016-02-02 Pharmaceutical composition for improving menopause and food and drink

Publications (3)

Publication Number Publication Date
JP2013079218A JP2013079218A (en) 2013-05-02
JP2013079218A5 true JP2013079218A5 (en) 2014-11-06
JP5899773B2 JP5899773B2 (en) 2016-04-06

Family

ID=48525918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011220787A Active JP5899773B2 (en) 2011-10-05 2011-10-05 Pharmaceutical composition for improving menopause and food and drink

Country Status (1)

Country Link
JP (1) JP5899773B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018043964A (en) * 2016-09-16 2018-03-22 サンスター株式会社 Sleep improving composition
JP2019011302A (en) * 2017-06-30 2019-01-24 サンスター株式会社 Composition for improving biorhythms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4647940B2 (en) * 2004-06-07 2011-03-09 花王株式会社 Aromatase activator
EP1855553A4 (en) * 2005-03-08 2012-03-14 Fonterra Co Operative Group High pressure processing of bioactive compositions
JP5033115B2 (en) * 2008-12-15 2012-09-26 株式会社Ｎｒｌファーマ Novel pharmaceutical composition and processed food for treating or preventing dry eye

Similar Documents

Publication Publication Date Title
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
MX2016016666A (en) Boronic acid derivatives and therapeutic uses thereof.
MX2016015093A (en) Boronic acid derivatives and therapeutic uses thereof.
EP2917180A4 (en) Gpr40 receptor agonist, methods of preparing the same, and pharmaceutical compositions containing the same as an active ingredient
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2014097151A3 (en) Autotaxin inhibitors
UA109868C2 (en) N -alkyltriazole compounds asr
JP2015525757A5 (en)
IT1404931B1 (en) OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES.
PH12015501096A1 (en) Composition for immediate and extended release
MX340985B (en) N-heteroaryl compounds.
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
EA201500513A1 (en) SOMICRONIZATION PRODUCT, INCLUDING ULETRIDAL ACETATE
UA117154C2 (en) S1p3 antagonists
JP2015500014A5 (en)
JP2009108025A5 (en)
JP2013523758A5 (en)
SMT201600243B (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANAKINRA WITHOUT CITRATE
NZ701103A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
JP2013079218A5 (en)